{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-120154","form_type":"8-K","ticker":"ITRMF","cik":"0001659323","company_name":"Iterum Therapeutics plc","filed_at":"2024-11-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.134432+00:00","generated_at":"2026-05-30T06:57:46.636916+00:00","sec_items":["2.03","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Iterum issues $20M promissory note to Pfizer at 8% interest for deferred milestone payment","bullets":["FDA approved ORLYNVAH (sulopenem) on Oct 25 for uncomplicated UTIs in adult women.","$20M regulatory milestone payment triggered under 2015 Pfizer license agreement.","Company elected to defer payment for 2 years (until Oct 25, 2026) via promissory note.","Note bears 8% annual interest compounded daily; prepayable without penalty.","Upon change of control during deferral, Pfizer may accelerate full payment plus interest."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-120154","json":"https://secwatch.observer/filing/0000950170-24-120154.json","markdown":"https://secwatch.observer/filing/0000950170-24-120154.md","text":"https://secwatch.observer/filing/0000950170-24-120154.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1659323/000095017024120154/0000950170-24-120154-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1659323/000095017024120154/itrm-20241028.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T06:57:46.636916+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}